Vanda ’s latest study failed. But revenue grew in 2019.

The D.C. biotech ’s phase 3 clinical trial of a drug candidate failed to reduce symptoms among adult patients with an itchy skin condition called atopic dermatitis.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 26, 2020 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news